Antengene Corporation, a Chinese clinical-stage therapeutics company focused on oncology, has secured a US$120 million in series B round of financing, jointly led by Boyu Capital and FountainVest, according to a statement released today. The new round also saw participation from Celgene Corporation, WuXi Corporate Venture Fund and Taikang. Existing investors, Qiming Venture Partners and […]
Boyu Capital Leads $120M Series B Round Into Oncology Medicine Developer Antengene appeared first on China Money Network.